Channels - Evaluation of Drug–Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)

Similar Items: Evaluation of Drug–Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)

Quick Look
Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
Quick Look
Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma
Quick Look
Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy
Quick Look
High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR‐SS Technology for Monitoring Advanced Urothelial Carcinoma
Quick Look
Common Bile Duct Diameter in Bladder Urothelial Carcinoma: A Case-Control Study
Quick Look
Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy
Quick Look
Comprehensive Evaluation of Drug-Related Problems and Pharmacotherapy Patterns in Non-Hodgkin’s Lymphoma Patients in Yemen
Quick Look
Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products
Quick Look
Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]
Quick Look
Cholesterol‐Lowering Treatment Blocks Epithelial‐Mesenchymal Transition (EMT) Associated Invasiveness and Drug Resistance in Breast and Colorectal Adenocarcinoma Models
Quick Look
Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma
Quick Look
Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer
Quick Look
Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab
Quick Look
Re: predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitors
Quick Look
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape
Quick Look
Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal Cancer
Quick Look
A retrospective review: The outcomes of patients with anal carcinoma receiving treatment at Groote Schuur Hospital
Quick Look
Clinical Factors Associated With Non‐Completion of Durvalumab Maintenance Therapy After Chemoradiotherapy in Patients With Locally Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study
Quick Look
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
Quick Look
Solid State microdosimetry for particle therapy: 25 years of developments at Centre for Medical Radiation Physics
Quick Look
Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
Quick Look
Efficacy and Safety of Regorafenib with or without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Systematic Review and Arm-Level Synthesis of Real-World Comparative Cohorts
Quick Look
Research Progress of HER2 in Cervical Carcinoma
Quick Look
Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors